Latest News

In today’s edition of Moneycontrol Pro Panorama: Gland Pharma’s poor streak cause for concern, no signs of recovery for Colgate, bailout cannot avert Pakistan#39;s crisis, Indian economy needs a time-out, and more

Read More

​ In today’s edition of Moneycontrol Pro Panorama: Gland Pharma’s poor streak cause for concern, no signs of recovery for Colgate, bailout cannot avert Pakistan#39;s crisis, Indian economy needs a time-out, and more In today’s edition of Moneycontrol Pro Panorama: Gland Pharma’s poor streak cause for concern, no signs of recovery for Colgate, bailout cannot avert Pakistan#39;s crisis, Indian economy needs a time-out, and more  Moneycontrol Latest News Read More  

In today’s edition of Moneycontrol Pro Panorama: Gland Pharma’s poor streak cause for concern, no signs of recovery for Colgate, bailout cannot avert Pakistan#39;s crisis, Indian economy needs a time-out, and more

NULL

Read More

​ NULL NULL  Moneycontrol Latest News Read More  

NULL

On the BSE, bank, power and realty indices shed 2 percent each and information technology, capital goods, healthcare and oil gas indices fell 1-1.7 percent.

Read More

​ On the BSE, bank, power and realty indices shed 2 percent each and information technology, capital goods, healthcare and oil gas indices fell 1-1.7 percent. On the BSE, bank, power and realty indices shed 2 percent each and information technology, capital goods, healthcare and oil gas indices fell 1-1.7 percent.  Moneycontrol Latest News Read More  

On the BSE, bank, power and realty indices shed 2 percent each and information technology, capital goods, healthcare and oil gas indices fell 1-1.7 percent.

Dr Reddy#39;s Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter.

Read More

​ Dr Reddy#39;s Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter. Dr Reddy#39;s Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter.  Moneycontrol Latest News Read More  

Dr Reddy#39;s Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter.

The multi-person operation that spans several months is spearheaded by finance secretary TV Somanathan and Arvind Shrivastava and PK Mishra from the Prime Minister’s Office

Read More

​ The multi-person operation that spans several months is spearheaded by finance secretary TV Somanathan and Arvind Shrivastava and PK Mishra from the Prime Minister’s Office The multi-person operation that spans several months is spearheaded by finance secretary TV Somanathan and Arvind Shrivastava and PK Mishra from the Prime Minister’s Office  Moneycontrol Latest News Read More  

The multi-person operation that spans several months is spearheaded by finance secretary TV Somanathan and Arvind Shrivastava and PK Mishra from the Prime Minister’s Office

Dr Reddy#39;s Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter.

Read More

​ Dr Reddy#39;s Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter. Dr Reddy#39;s Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter.  Moneycontrol Latest News Read More  

Dr Reddy#39;s Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter.

The stock fell 14 percent intraday on January 25, 2023, which is the steepest fall since January 24, 2022 when it saw a 19 percent drop

Read More

​ The stock fell 14 percent intraday on January 25, 2023, which is the steepest fall since January 24, 2022 when it saw a 19 percent drop The stock fell 14 percent intraday on January 25, 2023, which is the steepest fall since January 24, 2022 when it saw a 19 percent drop  Moneycontrol Latest News Read More  

The stock fell 14 percent intraday on January 25, 2023, which is the steepest fall since January 24, 2022 when it saw a 19 percent drop

SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.

Read More

​ SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing. SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.  Moneycontrol Latest News Read More  

SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.

In 2018, Balkrishna Doshi — who was known professionally as B.V. Doshi but was called just Doshi by nearly everyone — became the first Indian architect to receive the Pritzker Prize, considered architecture’s highest honor.

Read More

​ In 2018, Balkrishna Doshi — who was known professionally as B.V. Doshi but was called just Doshi by nearly everyone — became the first Indian architect to receive the Pritzker Prize, considered architecture’s highest honor. In 2018, Balkrishna Doshi — who was known professionally as B.V. Doshi but was called just Doshi by nearly everyone — became the first Indian architect to receive the Pritzker Prize, considered architecture’s highest honor.  Moneycontrol Latest News Read More  

In 2018, Balkrishna Doshi — who was known professionally as B.V. Doshi but was called just Doshi by nearly everyone — became the first Indian architect to receive the Pritzker Prize, considered architecture’s highest honor.

NULL

Read More

​ NULL NULL  Moneycontrol Latest News Read More  

NULL